Pharma channel feed – Endpoints News

Pharma channel feed

FDA's Scott Gottlieb is fielding a new team of recruiters to start scouting top talent

8 years ago

FDA keeps a firm grip on partial hold for troubled Repros Therapeutics, with big trial demand

8 years ago

FDA rejects Amgen’s osteoporosis drug romo as rival Radius surprises with a new CEO

8 years ago

White House doubles down on call to fund FDA entirely with industry fees

8 years ago

J&J gets a quick FDA OK for its blockbuster psoriasis contender guselkumab

8 years ago

Facing a critical August deadline, House passes bill to reauthorize FDA user fee programs

8 years ago

Pfizer’s data mining hits pay dirt as FDA panel backs a comeback for Mylotarg

8 years ago

Ocular Therapeutix's last-minute gambit fails to salvage its second FDA application, shares plunge

8 years ago

The biosimilar pack is growing around Roche’s all-star trio, looking to rip into a $21B franchise

8 years ago

FDA orders a rare retreat on Amicus’ migalastat, dropping PhIII demand and signaling a major shift for drug developers

8 years ago

After a quick trial revamp, FDA lifts its clinical hold on Concert’s hair-loss drug

8 years ago

Shire blasts Roche over its 'misleading' case for trailblazing hemophilia drug emicizumab, scoring injunction

8 years ago

Emmaus who? A biotech you never heard of just won an historic drug OK for sickle cell disease

8 years ago

Sanofi and Alnylam plunge into PhIII with a rival to Roche’s top hemophilia drug

8 years ago

J&J turns its back on Capricor and its failed stem cell tech, taking its money and rep with it

8 years ago

Dogged by accusations of shady sales practices, Alexion finds itself under investigation by HHS -- Bloomberg

8 years ago

Novartis turns to Oxford BioMedica for a major CAR-T supply deal

8 years ago

Celgene joins the PD-1 checkpoint club, bagging BeiGene drug with $413M down and $1B on the table

8 years ago

Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies

8 years ago

Personalized cancer vaccines stake their claim to the next frontier in immuno-oncology

8 years ago

In latest setback, another Coherus partner bails out on Amgen biosimilar deal

8 years ago

Merck left the door open to a devastating cyberattack, missing two chances to raise a defense

8 years ago

Shire’s Ornskov dictates another big revamp, with R&D/HQ moving into Cambridge

8 years ago

Omeros fires back after an online short attack whittles down its shares

8 years ago

First page Previous page 319 320 321322323 324 325 Next page Last page